ALPHA.PA · Pharnext SA
-
-
| Exchange | PA |
|---|---|
| CurrencyCode | EUR |
| ISIN | FR001400BV89 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Beta | -310.12 |
|---|---|
| Market Cap | 3K |
| PE Ratio | None |
| Target Price | 12500 |
| Dividend Yield | None |
ABOUT
Pharnext SA
Pharnext S.C.A., a clinical-stage biopharmaceutical company, engages in developing novel therapies for neurodegenerative diseases. Its products in clinical development include PXT3003, a synergistic combination of baclofen, naltrexone, and sorbitol formulated as an oral solution for the treatment of charcot-marie-tooth disease type 1A; and PXT864, a novel fixed-dose synergistic combination of baclofen and acamprosate formulated as a pill for neurodegenerative diseases. The company was incorporated in 2007 and is headquartered in Suresnes, France.
Learn More